Next-generation PARP inhibitor demonstrates clinical benefit in patients with homologous recombination repair-deficient breast cancer
SAN DIEGO – Saruparib, a selective inhibitor of poly-ADP ribose polymerase 1 (PARP1), demonstrated a promising objective response rate and progression-free survival in patients with certain homologous recombination repair (HRR)-deficient breast cancers, according to results from the phase I/II PETRA trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5-10.
Although blocking the enzyme PARP1 may be sufficient to prevent DNA repair in HRR-deficient tumors, all PARP inhibitors currently approved by the ...








